Nitrogen containing heterocycles as anticancer agents: a medicinal chemistry perspective

A Kumar, AK Singh, H Singh, V Vijayan, D Kumar… - Pharmaceuticals, 2023 - mdpi.com
Cancer is one of the major healthcare challenges across the globe. Several anticancer
drugs are available on the market but they either lack specificity or have poor safety, severe …

PI3K inhibitors in cancer: clinical implications and adverse effects

R Mishra, H Patel, S Alanazi, MK Kilroy… - International journal of …, 2021 - mdpi.com
The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway
which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian …

BCL-2 protein family: attractive targets for cancer therapy

D Kaloni, ST Diepstraten, A Strasser, GL Kelly - Apoptosis, 2023 - Springer
Acquired resistance to cell death is a hallmark of cancer. The BCL-2 protein family members
play important roles in controlling apoptotic cell death. Abnormal over-expression of pro …

Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer

M Mortazavi, F Moosavi, M Martini, E Giovannetti… - Critical reviews in …, 2022 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses among all
malignancies. PI3K/AKT/mTOR signaling pathway, a main downstream effector of KRAS is …

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

Q Li, Z Li, T Luo, H Shi - Molecular biomedicine, 2022 - Springer
Abstract The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by
mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling …

[HTML][HTML] Efficacy of PI3K inhibitors in advanced breast cancer

B Verret, J Cortes, T Bachelot, F Andre, M Arnedos - Annals of Oncology, 2019 - Elsevier
Abstract The phosphoinositide 3 (PI3)-kinase/Akt signaling pathway has always been a
focus of interest in breast cancer due to its role in cell growth, cell proliferation, cell migration …

Targeting PI3K/Akt/mTOR in AML: rationale and clinical evidence

S Darici, H Alkhaldi, G Horne, HG Jørgensen… - Journal of Clinical …, 2020 - mdpi.com
Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy
characterized by excessive proliferation and accumulation of immature myeloid blasts in the …

Development of PI3K inhibitors: Advances in clinical trials and new strategies

D Meng, W He, Y Zhang, Z Liang, J Zheng… - Pharmacological …, 2021 - Elsevier
Abstract Phosphatidylinositol 3-kinases (PI3Ks) are the family of vital lipid kinases widely
distributed in mammalian cells. The overexpression of PI3Ks leads to hyperactivation of the …

Mechanisms of resistance to PI3K inhibitors in cancer: adaptive responses, drug tolerance and cellular plasticity

SCE Wright, N Vasilevski, V Serra, J Rodon… - Cancers, 2021 - mdpi.com
Simple Summary The phosphoinositide-3-kinase (PI3K) pathway is the most frequently
activated pathway in human cancers. Consequently, a number of compounds targeting the …

The Magic Methyl and Its Tricks in Drug Discovery and Development

PSM Pinheiro, LS Franco, CAM Fraga - Pharmaceuticals, 2023 - mdpi.com
One of the key scientific aspects of small-molecule drug discovery and development is the
analysis of the relationship between its chemical structure and biological activity …